Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects

Antimicrobial Agents and Chemotherapy
Eric WenzlerKeith A Rodvold

Abstract

The steady-state concentrations of meropenem and the β-lactamase inhibitor RPX7009 in plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations were obtained in 25 healthy, nonsmoking adult subjects. Subjects received a fixed combination of meropenem (2 g) and RPX7009 (2 g) administered every 8 h, as a 3-h intravenous infusion, for a total of three doses. A bronchoscopy and bronchoalveolar lavage were performed once in each subject at 1.5, 3.25, 4, 6, or 8 h after the start of the last infusion. Meropenem and RPX7009 achieved a similar time course and magnitude of concentrations in plasma and ELF. The mean pharmacokinetic parameters ± the standard deviations of meropenem and RPX7009 determined from serial plasma concentrations were as follows: Cmax = 58.2 ± 10.8 and 59.0 ± 8.4 μg/ml, Vss = 16.3 ± 2.6 and 17.6 ± 2.6 liters; CL = 11.1 ± 2.1 and 10.1 ± 1.9 liters/h, and t1/2 = 1.03 ± 0.15 and 1.27 ± 0.21 h, respectively. The intrapulmonary penetrations of meropenem and RPX7009 were ca. 63 and 53%, respectively, based on the area under the concentration-time curve from 0 to 8 h (AUC0-8) values of ELF and total plasma concentrations. When unbound plasma concentrations were considered, ELF penetrations were 6...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Jun 1, 1992·Antimicrobial Agents and Chemotherapy·D R BaldwinR Wise
Jul 1, 1995·The Journal of Antimicrobial Chemotherapy·E M ParkerJ L Blumer
Aug 10, 2000·The Journal of Antimicrobial Chemotherapy·B AllegranziE Concia
Aug 19, 2003·Pharmacotherapy·Prachi K DandekarDavid P Nicolau
Nov 11, 2005·International Journal of Antimicrobial Agents·John E ConteElisabeth Zurlinden
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul G AmbroseGeorge L Drusano
Feb 9, 2011·Antimicrobial Agents and Chemotherapy·T P LodiseG L Drusano
Oct 18, 2011·Emerging Infectious Diseases·Patrice NordmannLaurent Poirel
Jan 25, 2013·The New England Journal of Medicine·Brad SpellbergDavid N Gilbert
Oct 2, 2013·Antimicrobial Agents and Chemotherapy·Matthew E FalagasGiannoula S Tansarli
Jan 1, 2014·Antimicrobial Agents and Chemotherapy·Sarah M DrawzRobert A Bonomo
Jun 14, 2014·Clinical Pharmacology and Therapeutics·T W FeltonW W Hope
Sep 14, 2014·The Journal of Antimicrobial Chemotherapy·Frédéric FrippiatMichel Moutschen
Nov 2, 2014·The Annals of Pharmacotherapy·Kimberly A Toussaint, Jason C Gallagher
Mar 18, 2015·Journal of Medicinal Chemistry·Scott J HeckerMichael N Dudley
Apr 13, 2015·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I Olsen

❮ Previous
Next ❯

Citations

Sep 20, 2016·MedChemComm·Jesse A JonesKirk E Hevener
Jul 13, 2016·Expert Review of Anti-infective Therapy·Matthew E FalagasKonstantinos Z Vardakas
Dec 29, 2016·Current Opinion in Infectious Diseases·Mohd H Abdul-AzizJason A Roberts
Mar 18, 2017·Drugs·Darren Wong, David van Duin
Mar 8, 2018·Current Infectious Disease Reports·Nathaniel J RhodesAlan R Hauser
Feb 11, 2018·Pharmacotherapy·Sarah Christina Jane Jorgensen, Michael Joseph Rybak
Oct 19, 2017·Antimicrobial Agents and Chemotherapy·Debora Rubio-AparicioOlga Lomovskaya
Mar 9, 2018·The Annals of Pharmacotherapy·Jonathan C ChoJoe Pardo
Jan 10, 2018·Antimicrobial Agents and Chemotherapy·Christopher M RubinoDavid C Griffith
Jul 24, 2018·Expert Opinion on Emerging Drugs·Marco ManteroMarta Di Pasquale
Aug 15, 2018·Expert Opinion on Drug Metabolism & Toxicology·Rodrigo M BurgosLarry H Danziger
Oct 30, 2018·Expert Review of Anti-infective Therapy·Owen R AlbinKeith S Kaye
Sep 4, 2018·British Journal of Clinical Pharmacology·Dagan O LonsdaleJoseph F Standing
Jan 11, 2019·Expert Opinion on Drug Metabolism & Toxicology·Ilias KaraiskosHelen Giamarellou
Dec 28, 2018·Pharmacotherapy·Ryan L Crass, Manjunath P Pai
Jan 26, 2018·Pharmaceutical Research·Linda B S AulinJ G Coen van Hasselt
Nov 19, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ryan K ShieldsM Hong Nguyen
Apr 17, 2020·Expert Review of Anti-infective Therapy·Andrea NovelliMario Tumbarello
May 20, 2020·Antimicrobial Agents and Chemotherapy·Christian M GillDavid P Nicolau
Dec 8, 2016·Current Infectious Disease Reports·Dana R Bowers, Vanthida Huang
Jan 28, 2018·Expert Opinion on Drug Metabolism & Toxicology·Marco FalconeManjunath Pai
Apr 21, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Young R Lee, Nathaniel T Baker
Mar 14, 2019·The Journal of Antimicrobial Chemotherapy·Wesley D KufelBryan T Mogle
Aug 31, 2016·Expert Review of Anti-infective Therapy·D LeoniJ Rello
Oct 8, 2020·Infectious Diseases and Therapy·Eric Wenzler, Patrick J Scoble
Oct 23, 2020·Expert Opinion on Pharmacotherapy·Lauren M GroftEmily L Heil
Nov 13, 2020·Clinical Microbiology Reviews·Dafna YahavLeonard Leibovici
Apr 15, 2021·Expert Review of Clinical Pharmacology·Anselm Jorda, Markus Zeitlinger
Jul 3, 2021·Antibiotics·Giacomo LuciAntonello Di Paolo
Jun 29, 2021·Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine·Isabella Princess, Rohit Vadala
Oct 16, 2021·Clinical Pharmacokinetics·Emily N Drwiega, Keith A Rodvold
Oct 28, 2021·International Journal of Antimicrobial Agents·Wei YuYunqing Qiu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.